• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020

tetano

Editor, Senior Moderator
Emerg Infect Dis


. 2021 Mar 23;27(5).
doi: 10.3201/eid2705.204661. Online ahead of print.
Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020

Alexandra K Heaney, Jennifer R Head, Kelly Broen, Karen Click, John Taylor, John R Balmes, Jon Zelner, Justin V Remais

Abstract

We review the interaction between coronavirus disease (COVID-19) and coccidioidomycosis, a respiratory infection caused by inhalation of Coccidioides fungal spores in dust. We examine risk for co-infection among construction and agricultural workers, incarcerated persons, Black and Latino populations, and persons living in high dust areas. We further identify common risk factors for co-infection, including older age, diabetes, immunosuppression, racial or ethnic minority status, and smoking. Because these diseases cause similar symptoms, the COVID-19 pandemic might exacerbate delays in coccidioidomycosis diagnosis, potentially interfering with prompt administration of antifungal therapies. Finally, we examine the clinical implications of co-infection, including severe COVID-19 and reactivation of latent coccidioidomycosis. Physicians should consider coccidioidomycosis as a possible diagnosis when treating patients with respiratory symptoms. Preventive measures such as wearing face masks might mitigate exposure to dust and severe acute respiratory syndrome coronavirus 2, thereby protecting against both infections.

Keywords: Arizona; COVID-19; California; Coccidioides; SARS-CoV-2; United States; co-infections; coccidioidomycosis; coronavirus disease; coronaviruses; diagnosis; fungi; respiratory infections; risk factors; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
 
Back
Top Bottom